Sign Up Today and Learn More About Mammoth Biosciences Stock
Invest in or calculate the value of your shares in Mammoth Biosciences or other pre-IPO companies through EquityZen's platform.
Mammoth Biosciences Stock (MABI)
Mammoth Biosciences leverages its proprietary ultra-compact CRISPR platform for gene editing therapies. They focus on in vivo delivery, aiming for long-term cures for life-threatening diseases. Their protein discovery pipeline seeks novel CRISPR systems with functionalities beyond double-stranded breaks, including base and epigenetic editing. Co-founded by CRISPR pioneer Jennifer Doudna.
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
About Mammoth Biosciences Stock
Founded
2017
Total Funding
365M
Industries
Science and Engineering, Health Care, Biotechnology
Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems.Â
Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.
Mammoth Biosciences Press Mentions
Stay in the know about the latest news on Mammoth Biosciences
CRISPR Gene Detection and Diagnostic Markets Report 2024: Unlimited Potential from a Startling Technology, Simultaneous Detection of Multiple Gene Targets Opens Up Huge Market Opportunities
globenewswire • Nov 29, 2024
How biotech startups become unicorns
labiotech • Nov 16, 2024
ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities
genengnews • Aug 03, 2024
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines
medcitynews • May 23, 2024
Regeneron signs Mammoth gene editing deal worth $100M upfront
fiercebiotech • May 23, 2024
Investors in Mammoth Biosciences
Discover investors in Mammoth Biosciences stock and explore their portfolio companies
Mammoth Biosciences Management
Leadership team at Mammoth Biosciences
Chief Executive Officer
Trevor Martin
Chief Financial Officer
Elaine Sun
Join now and verify your accreditation status to gain access to:
- Mammoth Biosciences current valuation
- Mammoth Biosciences stock price
- Available deals in Mammoth Biosciences and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Mammoth Biosciences Stock
How to invest in Mammoth Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Mammoth Biosciences through EquityZen funds. These investments are made available by existing Mammoth Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mammoth Biosciences stock?
Shareholders can sell their Mammoth Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
